Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia
Blood Vessels, Thrombosis & Hemostasis · 2026-05 · 3 (2) · 100167
DOI: 10.1016/j.bvth.2026.100167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-05. Verfasst von Tomás José González-López und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by both impaired platelet production and accelerated immune-mediated platelet destruction. Central pathogenic mechanisms include autoreactive B-cell expansion, production of antiplatelet antibodies, Fc γ -mediated phagocytosis, and dysregulated T-cell immunity. 1 Although corticosteroids, thrombopoietin receptor agonists (TPO-RAs), rituximab, and splenectomy remain standard treatment options, many patients experience relapse, partial response, or multirefractory disease. 1 These patients represent a significant therapeutic challenge and often require treatments with novel mechanisms of action mechanisms of action. Bruton tyrosine kinase (BTK) plays a pivotal role in B-cell receptor signaling and in Fc γ -mediated macrophage activation, making it a compelling therapeutic target in antibody-mediated cytopenias. 2,3 Rilzabrutinib’s reversible covalent BTK inhibition differs mechanistically from the irreversible BTK inhibitors (BTKi) used in lymphoid malignancies, potentially minimizing
Autor:innen und Institutionen
- Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain.
- Pharmacy Service, Hospital Universitario de Burgos, Burgos, Spain.
- Department of Hematology, Hospital General Sierrallana-Tres Mares, Torrelavega, Spain.
- Research Unit, Fundación Burgos por la Investigación de la Salud, Hospital Universitario de Burgos, Burgos, Spain.
- Department of Hematology, Hospital Privado Rosario, Rosario, Argentina.
- Department of Haematology, Barts and The London School of Medicine, London, United Kingdom.
Zitieren
APA
González-López, T. J., Orza, F., Cuesta-García, A., Pérez-Gómez, N., Fedele, J. L., Provan, D., & Kuter, D. J. (2026). Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia. Blood Vessels, Thrombosis & Hemostasis, 3(2), 100167. https://doi.org/10.1016/j.bvth.2026.100167
Vancouver
González-López TJ, Orza F, Cuesta-García A, Pérez-Gómez N, Fedele JL, Provan D, et al. Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia. Blood Vessels, Thrombosis & Hemostasis. 2026;3(2):100167. doi:10.1016/j.bvth.2026.100167
BibTeX
@article{GonzlezLpez2026,
author = {González-López, Tomás José and Orza, Fernando and Cuesta-García, Amalia and Pérez-Gómez, Noelia and Fedele, José Luis and Provan, Drew and Kuter, David J},
title = {Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
volume = {3},
number = {2},
pages = {100167},
doi = {10.1016/j.bvth.2026.100167}
}
EUVIMED